LGALS3BP and neuroblastoma: This work proved that ADC-therapy targeting LGALS3BP in neuroblastoma induced significant shrinkage of established subcutaneous and orthotopic neuroblastomas, as well as inhibition of metastatic dissemination and complete eradication of subcutaneous high-risk neuroblastoma patient-derived xenografts (PDX)s harboring MYCN amplification.